Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schumacher, D. L.
Right arrow Articles by Staren, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schumacher, D. L.
Right arrow Articles by Staren, E. D.

Annals of Surgical Oncology, Vol 1, Issue 5 378-381, Copyright © 1994 by Society of Surgical Oncology

ARTICLES

Peritoneovenous shunts for palliation of the patient with malignant ascites

D. L. Schumacher, T. J. Saclarides and E. D. Staren
Department of General Surgery, Rush Medical College, Chicago, Illinois.

METHODS: This study evaluated the effectiveness and morbidity associated with 116 peritoneovenous shunts inserted into 89 patients for symptomatic malignant ascites between 1981 and 1991. All patients had previously failed standard medical therapy of salt and fluid restriction, diuretics, and intermittent peritoneal aspirations. RESULTS: Symptoms from the ascites included discomfort, impaired mobility, early satiety, and dyspnea. The study population was composed of 31 men and 58 women whose ages ranged from 24 to 81 years (mean 56). Primary tumors originated from the following sites: breast, 17; ovary, 17; pancreas, 13; gastrointestinal or related organs, 21; and other sites, 21. Mean shunt patency was 83 days; however, only 31% of the patients studied maintained a patent shunt and lived for > 2 months. Symptomatic relief was achieved in only 57 patients (62%). Forty-four patients (49%) developed one or more complications related to shunt placement. The deaths of 12 patients (13%) within 30 days of surgery were directly related to a complication of shunt placement. Overall, 30- and 60-day mortality rates were 43% and 61%, respectively. CONCLUSIONS: Due to the brief and only fair relief of symptoms with a high associated morbidity and mortality, we believe peritoneovenous shunts are of very limited usefulness in the palliation of malignant ascites and suggest that alternate methods should be considered to manage these patients.


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
N. Aslam and C. R. Marino
Malignant Ascites: New Concepts in Pathophysiology, Diagnosis, and Management
Arch Intern Med, December 10, 2001; 161(22): 2733 - 2737.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H.M.W. Verheul, K. Hoekman, A.S. Jorna, E.F. Smit, and H.M. Pinedo
Targeting Vascular Endothelial Growth Factor Blockade: Ascites and Pleural Effusion Formation
Oncologist, April 1, 2000; 5(90001): 45 - 50.
[Abstract] [Full Text]

Home page
 Ann. Thorac. Surg.Home page
C. K. Chiu, D. M. Nagorney, and H. V. Schaff
Hepatoatrial anastomosis and tricuspid valve replacement in Budd-Chiari syndrome 8.
Ann. Thorac. Surg., November 1, 1998; 66(5): 1803 - 1804.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the Society of Surgical Oncology.